Clinical trial · Interventional
Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy
Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy Monocentric, Comparative, Randomized, Open Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prostate cancer is the first cancer in men. The treatment of metastatic prostate cancer with chemotherapy is based on the intravenous administration of docetaxel chemotherapy. Symptoms of anticipatory nausea, linked to anxiety caused by the treatment, may occur. Hypnosis is already used to treat the anxiety of people with cancer and can help treat the symtoms of nausea and vomiting of women with breast cancer. The purpose of the study is to evaluate the effect of medical hypnosis in virtual reality on the anxiety of patients with metastatic prostate cancer receiving Docetaxel chemotherapy treatment in comparison with a control group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| HYPNO VR® device | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- HypnoVR Arm
- description
- During each Docetaxel infusion, patients benefit from a 20-minute session of medical hypnosis in virtual reality.
- interventionNames
- Device: HYPNO VR® device
- type
- NO_INTERVENTION
- label
- Control Arm
- description
- Patients receive the docetaxel infusions under standard conditions (no medical hypnosis in virtual reality intervention)
Primary outcomes (1)
- measure
- Demonstrate a modification in anxiety after each infusion of Docetaxel in the HypnoVR arm compared to the control arm.
- timeFrame
- For up to 6 months, every 2 weeks (before and after the 12 infusions), starting on day of first infusion until day of the last twelfth infusion
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Man aged ≥ 18 years * Histologically proven metastatic prostate adenocarcinoma, * Patient undergoing chemotherapy according to the following conventional scheme: 12 courses of Docetaxel every two weeks * Patient who signed their informed consent * Patient benefiting from social security coverage * Patient treated and followed in the center for the duration of the study (6 months maximum). Exclusion Criteria: * Patient participating in another clinical trial on an experimental molecule * Patient who received previous chemotherapy * Patient unable to submit to protocol monitoring for psychological, social, family or geographic reasons * Patient deprived of their liberty or under guardianship * Patient with underlying or concomitant pathology incompatible with inclusion in the trial, whether psychiatric or somatic
References
Publications (0)
Data not yet available